Drug Profile
Lansoprazole immediate release - TAP/Santarus
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TAP Pharmaceutical Products
- Developer Santarus; TAP Pharmaceutical Products
- Class Antiulcers; Benzimidazoles; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 07 Mar 2006 TAP Pharmaceutical Products terminates its sublicence for immediate-release proton pump inhibitor (PPI) technology
- 07 Mar 2006 Discontinued - Preclinical for Gastrointestinal disorders in USA (unspecified route)
- 07 Mar 2006 Santarus received a US$10 million milestone payment, plus interest and legal expenses, from TAP Pharmaceutical Products